Get the Stockscreener App
14.79
2.12%
-0.32
Pre-market:
15.19
0.40
+2.70%
Uniqure N V stock is traded at $14.79, with a volume of 1.97M.
It is down -2.12% in the last 24 hours and up +7.96% over the past month.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
See More
Previous Close:
$15.11
Open:
$15.01
24h Volume:
1.97M
Relative Volume:
1.12
Market Cap:
$894.59M
Revenue:
$15.84M
Net Income/Loss:
$-308.48M
P/E Ratio:
-2.2824
EPS:
-6.48
Net Cash Flow:
$-153.08M
1W Performance:
-9.49%
1M Performance:
+7.96%
6M Performance:
-10.15%
1Y Performance:
+215.35%
1-Day Range:
$14.40
$15.13
1-Week Range:
$14.40
$17.14
52-Week Range:
$3.73
$19.18
Uniqure N V Stock (QURE) Company Profile
Name
Uniqure N V
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
14.79 | 894.59M | 15.84M | -308.48M | -153.08M | -6.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-01-25 | Resumed | Chardan Capital Markets | Buy |
| Dec-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Feb-29-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-19-23 | Downgrade | Mizuho | Buy → Neutral |
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure N V Stock (QURE) Latest News
uniQure: Price And Value Have Caught Up (NASDAQ:QURE) - Seeking Alpha
uniQure shareholders approve executive compensation, board reappointments By Investing.com - Investing.com South Africa
uniQure shareholders approve executive compensation, board reappointments - Investing.com
uniQure (QURE) Appoints Kylie O'Keefe to Advance Global Strategy - GuruFocus
uniQure appoints Kylie O’Keefe as Chief Customer and Strategy Officer By Investing.com - Investing.com South Africa
uniQure appoints Kylie O’Keefe as Chief Customer and Strategy Officer - Investing.com India
uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer - GlobeNewswire
uniQure Prepares for Historic Huntington's Disease Treatment Launch with Key Executive Hire - Stock Titan
uniQure (NASDAQ:QURE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Learn to Evaluate (QURE) using the Charts - news.stocktradersdaily.com
uniQure (QURE) Positioned for Growth Amid Regulatory Changes - GuruFocus
RFK Jr. looks to fast track rare disease drug approvals (updated) - Seeking Alpha
Bank of America Corp DE Has $1.22 Million Stock Holdings in uniQure (NASDAQ:QURE) - Defense World
Stock Traders Buy Large Volume of uniQure Call Options (NASDAQ:QURE) - Defense World
stifel reiterates buy rating on uniQure stock after CEO meeting By Investing.com - Investing.com UK
uniQure (NASDAQ:QURE) Short Interest Update - Defense World
H.C. Wainwright reaffirms Buy rating on uniQure stock after FDA meeting By Investing.com - Investing.com South Africa
H.C. Wainwright reaffirms Buy rating on uniQure stock after FDA meeting - Investing.com Australia
Chardan Capital Reaffirms Buy Rating for uniQure (NASDAQ:QURE) - MarketBeat
uniQure aligns with FDA on Huntington’s therapy path By Investing.com - Investing.com South Africa
uniQure provides regulatory update on AMT-130 for Huntington’s Disease - TipRanks
UniQure Reaches Alignment With FDA on Potential Huntington's Disease Gene Therapy - marketscreener.com
Transcript : UniQure N.V.Special Call - marketscreener.com
UniQure Provides Regulatory Update On Amt-130 For Huntington'S Disease - marketscreener.com
uniQure (QURE) Advances Gene Therapy for Huntington's Disease wi - GuruFocus
uniQure aligns with FDA on Huntington’s therapy path - Investing.com
uniQure (QURE) Advances Gene Therapy for Huntington's Disease with FDA Alignment | QURE Stock News - GuruFocus
uniQure Advances AMT-130 for Huntington's Disease with FDA Alignment, BLA Submission Planned for Q1 2026 - Nasdaq
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease - GlobeNewswire
FDA Green Lights Accelerated Approval Plan for First-Ever Huntington's Disease Gene Therapy Treatment - Stock Titan
uniQure (NASDAQ:QURE) Given “Buy” Rating at Chardan Capital - Defense World
HC Wainwright maintains Buy rating on uniQure stock, $70 target By Investing.com - Investing.com UK
uniQure (NASDAQ:QURE) Receives Buy Rating from HC Wainwright - Defense World
QURE: HC Wainwright & Co. Reiterates Buy Rating for uniQure | QU - GuruFocus
uniQure presents case study of first patient dosed with AMT-260 - TipRanks
uniQure (QURE) Gains Support Following Positive Data from Epilep - GuruFocus
uniQure (QURE) Unveils Key Data from Gene Therapy Trial | QURE S - GuruFocus
uniQure early AMT-260 data encouraging, says H.C. Wainwright - TipRanks
uniQure (QURE) Unveils Key Data from Gene Therapy Trial | QURE Stock News - GuruFocus
uniQure Presents Clinical Case Study of First Patient Dosed - GlobeNewswire
uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE) | QURE Stock News - GuruFocus
Revolutionary Gene Therapy Cuts Epilepsy Seizures by 92% in First Patient DataUniQure's Breakthrough - Stock Titan
Down 40% in 2025, Should You Buy the Dip in Marvell Stock? - The Globe and Mail
Long Term Trading Analysis for (QURE) - news.stocktradersdaily.com
uniQure's AMT-130 Gene Therapy Warrants An Upgrade (NASDAQ:QURE) - Seeking Alpha
Northern Trust Corp Buys 1,923 Shares of uniQure (NASDAQ:QURE) - Defense World
Millennium Management LLC Cuts Position in uniQure (NASDAQ:QURE) - Defense World
uniQure (NASDAQ:QURE) Upgraded at Wall Street Zen - Defense World
uniQure N.V. (QURE) Stock Analysis: Exploring a 133.81% Potential Upside in Biotechnology - DirectorsTalk Interviews
Fed. Circ. Backs Pfizer Win Against Gene Therapy Patents - Law360
Stock Traders Purchase High Volume of Put Options on uniQure (NASDAQ:QURE) - Defense World
Uniqure N V Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):